SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cytrx Corp – ‘10-K’ for 12/31/16 – ‘EX-31.2’

On:  Wednesday, 3/15/17, at 3:19pm ET   ·   For:  12/31/16   ·   Accession #:  799698-17-12   ·   File #:  0-15327

Previous ‘10-K’:  ‘10-K’ on 3/11/16 for 12/31/15   ·   Next:  ‘10-K’ on 3/16/18 for 12/31/17   ·   Latest:  ‘10-K’ on 3/27/24 for 12/31/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/15/17  Cytrx Corp                        10-K       12/31/16   85:8.5M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report on Form 10-K for Year Ending Dec.     HTML   1.05M 
                31, 2016                                                         
 2: EX-4.6      Form of Warrant Dated July 20, 2016                 HTML    107K 
 3: EX-4.7      Contingent Common Stock Purchase Warrant            HTML     72K 
 4: EX-4.8      Emmanuel Warrant Issued on November 10, 2013        HTML     87K 
 5: EX-4.9      Emmanuel Warrant                                    HTML     74K 
 6: EX-10.26    2017 Employment Agreement - Daniel Levitt, M.D.,    HTML    101K 
                Ph.D.                                                            
 7: EX-10.29    2017 Employment Agreement - Scott Wieland           HTML     79K 
 8: EX-10.30    2017 Employment Agreement - John Caloz              HTML     79K 
 9: EX-10.31    2017 Employment Agreement - Olivia Ware             HTML     81K 
10: EX-10.38    2017 Amendment to Employment Agreement - Steven A.  HTML     30K 
                Kriegsman                                                        
11: EX-10.39    Restricted Stock Purchase Agreement Dated January   HTML     46K 
                11, 2017                                                         
12: EX-23.1     Consent of Independent Accounting Firm              HTML     23K 
13: EX-31.1     Certification of Chief Executive Officer            HTML     30K 
14: EX-31.2     Certification of Chief Financial Officer            HTML     29K 
15: EX-32.1     Certification of Chief Executive Officer (SEC.      HTML     24K 
                1350)                                                            
16: EX-32.2     Certification of Chief Financial Officer (SEC.      HTML     25K 
                1350)                                                            
23: R1          Document and Entity Information                     HTML     51K 
24: R2          Balance Sheets                                      HTML    101K 
25: R3          Balance Sheets (Parenthetical)                      HTML     51K 
26: R4          Statements of Operations                            HTML     66K 
27: R5          Statements of Stockholders' Equity                  HTML    118K 
28: R6          Statements of Cash Flows                            HTML    128K 
29: R7          Nature of Business                                  HTML     34K 
30: R8          Summary of Significant Accounting Policies          HTML     83K 
31: R9          Foreign Currency Remeasurement                      HTML     29K 
32: R10         Receivables                                         HTML     28K 
33: R11         Prepaid and Other Assets                            HTML     25K 
34: R12         Short-term Investments                              HTML     28K 
35: R13         Equipment and Furnishings                           HTML     34K 
36: R14         Accrued Expenses and Other Current Liabilities      HTML     34K 
37: R15         Non-Cash Litigation Settlement Due in Shares of     HTML     26K 
                Common Stock                                                     
38: R16         Term Loan                                           HTML     41K 
39: R17         Warrant Liabilities                                 HTML     41K 
40: R18         Commitments and Contingencies                       HTML     62K 
41: R19         Equity Transactions                                 HTML     36K 
42: R20         Stock Options and Equity-Classified Warrants        HTML    218K 
43: R21         Stockholder Protection Rights Plan                  HTML     28K 
44: R22         Income Taxes                                        HTML     66K 
45: R23         Earnings (Loss) Per Share                           HTML     31K 
46: R24         Quarterly Financial Data (Unaudited)                HTML     49K 
47: R25         Subsequent Event                                    HTML     25K 
48: R26         Schedule Ii - Valuation and Qualifying Accounts     HTML     42K 
49: R27         Summary of Significant Accounting Policies          HTML    132K 
                (Policies)                                                       
50: R28         Summary of Significant Accounting Policies          HTML     53K 
                (Tables)                                                         
51: R29         Equipment and Furnishings (Tables)                  HTML     32K 
52: R30         Accrued Expenses and Other Current Liabilities      HTML     34K 
                (Tables)                                                         
53: R31         Term Loan (Tables)                                  HTML     42K 
54: R32         Warrant Liabilities (Tables)                        HTML     39K 
55: R33         Commitments and Contingencies (Tables)              HTML     46K 
56: R34         Stock Options and Equity-Classified Warrants        HTML    219K 
                (Tables)                                                         
57: R35         Income Taxes (Tables)                               HTML     62K 
58: R36         Earnings (Loss) Per Share (Tables)                  HTML     29K 
59: R37         Quarterly Financial Data (Unaudited) (Tables)       HTML     48K 
60: R38         Nature of Business (Details)                        HTML     68K 
61: R39         Summary of Significant Accounting Policies          HTML     69K 
                (Details)                                                        
62: R40         Foreign Currency Remeasurement (Details)            HTML     27K 
63: R41         Receivables (Details)                               HTML     26K 
64: R42         Prepaid and Other Assets (Details)                  HTML     26K 
65: R43         Short-term Investments (Details)                    HTML     25K 
66: R44         Equipment and Furnishings (Details)                 HTML     35K 
67: R45         Accrued Expenses and Other Current Liabilities      HTML     38K 
                (Details)                                                        
68: R46         Non-Cash Litigation Settlement Due in Shares of     HTML     30K 
                Common Stock (Details)                                           
69: R47         Term Loan (Details)                                 HTML     75K 
70: R48         Warrant Liabilities (Details)                       HTML     47K 
71: R49         Commitments and Contingencies (Details)             HTML    107K 
72: R50         Equity Transactions (Details)                       HTML    111K 
73: R51         Stock Options and Equity-Classified Warrants        HTML    199K 
                (Details)                                                        
74: R52         Stock Options and Equity-Classified Warrants,       HTML     37K 
                Schedule of Employee and Non Employee Service                    
                Share Based Compensation (Details)                               
75: R53         Stock Options and Equity-Classified Warrants,       HTML     87K 
                Options by Exercise Price Range (Details)                        
76: R54         Stock Options and Equity-Classified Warrants,       HTML     76K 
                Warrants, Shares Purchased and Intrinsic Value                   
                (Details)                                                        
77: R55         Stockholder Protection Rights Plan (Details)        HTML     36K 
78: R56         Income Taxes (Details)                              HTML    113K 
79: R57         Earnings (Loss) Per Share (Details)                 HTML     40K 
80: R58         Quarterly Financial Data (Unaudited) (Details)      HTML     35K 
81: R59         Subsequent Event (Details)                          HTML     32K 
82: R60         Schedule Ii - Valuation and Qualifying Accounts     HTML     35K 
                (Details)                                                        
84: XML         IDEA XML File -- Filing Summary                      XML    127K 
83: EXCEL       IDEA Workbook of Financial Reports                  XLSX     78K 
18: EX-101.INS  XBRL Instance -- cytr-20161231                       XML   2.03M 
20: EX-101.CAL  XBRL Calculations -- cytr-20161231_cal               XML    209K 
21: EX-101.DEF  XBRL Definitions -- cytr-20161231_def                XML    648K 
17: EX-101.LAB  XBRL Labels -- cytr-20161231_lab                     XML   1.78M 
22: EX-101.PRE  XBRL Presentations -- cytr-20161231_pre              XML   1.03M 
19: EX-101.SCH  XBRL Schema -- cytr-20161231                         XSD    178K 
85: ZIP         XBRL Zipped Folder -- 0000799698-17-000012-xbrl      Zip    193K

‘EX-31.2’   —   Certification of Chief Financial Officer

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

 C: 

Exhibit 31.2

CERTIFICATIONS

I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:
1. I have reviewed this annual report on Form 10-K of CytRx Corporation;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
  CYTRX CORPORATION  
       
March 15, 2017
By:
/s/ JOHN Y. CALOZ  
    John Y. Caloz  
    Chief Financial Officer  
       

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/15/178-K,  8-K/A
For Period end:12/31/16
 List all Filings 
↑Top
Filing Submission 0000799698-17-000012   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 4:50:18.1am ET